| EPB114 | Weight change when discontinuing integrase strand transfer inhibitors in people living with HIV | E-poster | Weight gain |
| EPB115 | Weight gain after non-nucleoside reverse transcriptase-to-integrase inhibitor switch in the United States | E-poster | Weight gain |
| EPB116 | Change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide vs. a dolutegravir-based regimen among a prospective longitudinal cohort of virologically suppressed adults living with HIV | E-poster | Weight gain |
| EPB117 | Preferences for weight gain compared with other antiretroviral therapy side effects among people living with HIV: a discrete choice experiment | E-poster | Weight gain |
| EPB118 | Longitudinal analysis of weight change in HIV-1 treatment-naïve and -experienced people living with HIV (PLWH) initiating/switching to an NNRTI- or InSTI-based antiretroviral therapy in four large cohort studies | E-poster | Weight gain |
| EPB119 | Weight changes and pregnancy outcomes among pregnant people living with HIV in use of integrase inhibitors initiated before or after conception: a cohort study | E-poster | Weight gain |
| EPB120 | Association between Dolutegravir use and weight gain among adults in Tanzania | E-poster | Weight gain |
| EPB121 | Bictegravir-containing ART regimens and weight gain in children with perinatal HIV | E-poster | Weight gain |
| EPB122 | Non-invasive identification of severe NAFLD and risk stratification of clinical outcomes using Fibroscan-AST (FAST) score in 1683 people with HIV | E-poster | Hepatic complications (e.g., NASH) |
| EPB123 | Incidence and disease severity of non-alcoholic fatty liver disease among people living with HIV in Thailand | E-poster | Hepatic complications (e.g., NASH) |